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Background: Although the mechanisms underlying the beneficial effects of estrogen on cerebrovascular function
are well known, the age-dependent deleterious effects of estrogen are largely unstudied. It was hypothesized that
age and sex interact in modulating cerebrovascular reactivity to vasopressin (VP) by altering the role of prostanoids
in vascular function.
Methods: Female (F) Sprague–Dawley rats approximating key stages of “hormonal aging” in humans were studied:
premenopausal (mature multigravid, MA, cyclic, 5–6 months) and postmenopausal (reproductively senescent, RS,
acyclic, 10–12 months). Age-matched male (M) rats were also studied. Reactivity to VP (10−12–10−7 M) was measured in
pressurized middle cerebral artery segments in the absence or presence of selective inhibitors of COX-1 (SC560, SC,
1 μM) or COX-2 (NS398, NS, 10 μM). VP-stimulated release of PGI2 and TXA2 were measured using radioimmunoassay
of 6-keto-PGF1α and TXB2 (stable metabolites, pg/mg dry wt/45 min).
Results: In M, there were no changes in VP-induced vasoconstriction with age. Further, there were no significant
differences in basal or in low- or high-VP-stimulated PGI2 or TXA2 production in younger or older M. In contrast, there
were marked differences in cerebrovascular reactivity and prostanoid release with advancing age in F. Older RS F
exhibited reduced maximal constrictor responses to VP, which can be attributed to enhanced COX-1 derived dilator
prostanoids. VP-induced vasoconstriction in younger MA F utilized both COX-1 and COX-2 derived constrictor
prostanoids. Further, VP-stimulated PGI2 and TXA2 production was enhanced by endogenous estrogen and decreased
with advancing age in F, but not in M rats.
Conclusions: This is the first study to examine the effects of age and sex on the mechanisms underlying
cerebrovascular reactivity to VP. Interestingly, VP-mediated constriction was reduced by age in F, but was
unchanged in M rats. Additionally, it was observed that selective blockade of COX-1 or COX-2 produced
age-dependent changes in cerebrovascular reactivity to VP and that VP-stimulated PGI2 and TXA2 production
were enhanced by endogenous estrogen in younger F. A better understanding of the mechanisms by which
estrogen exerts its effects may lead to new age- and sex-specific therapeutic agents for the prevention and/or
treatment of cerebrovascular diseases.
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The human aging process is associated with marked sex-
ual dimorphism in the incidences of neurological and
vascular diseases, but the reasons for these sex diffe-
rences in disease are unclear [1]. Premenopausal women
exhibit lower incidences of cardiovascular disease and
stroke than males of the same age, yet after menopause,
these differences dissipate. Because the risks of cardio-
vascular disease and stroke increase with the onset of
menopause, estrogen has been implicated as protective
against these diseases. Indeed, estrogen appears to play a
fundamental role in the maintenance of both neuronal
and vascular health in younger women and to be pro-
tective against diseases such as coronary artery disease,
hypertension, and stroke [2-5]. In numerous animal stud-
ies, estrogen exerts beneficial effects by (1) enhancing
vasodilator factors, including nitric oxide and prostacyclin
(PGI2), (2) increasing expression and/or activity of endo-
thelial nitric oxide synthase (eNOS), cyclooxygenase-1
(COX-1), and prostacyclin synthase proteins, and (3)
stimulating the phosphatidylinositol 3-kinase/Akt path-
way, which increases eNOS phosphorylation, eNOS activ-
ity, and subsequently nitric oxide production [6].
Disruption of the endocrine environment, both during
menopause and with advancing age, contributes to dra-
matic increases in the incidence of neurodegenerative
and vascular diseases, especially stroke. While both en-
dogenous estrogens and estrogen replacement therapy
following surgical menopause exert beneficial effects in
younger females (F), age and/or estrogen replacement
therapy appear to be detrimental in older, postmeno-
pausal F. In fact, epidemiological and experimental stu-
dies revealed that both age and estrogen replacement
therapy increase the risk for stroke and the extent of
brain injury following ischemic stroke in aged F [7]. Re-
cent studies in the systemic vasculature demonstrated
that estrogen enhances the production of, and reactivity
to, thromboxane (TXA2) and other deleterious con-
strictor prostanoids in the F Sprague–Dawley rat [8,9].
Thus, it is important to determine how age and sex
interact in the regulation of cerebrovascular prostanoid
production and the enhancement of both vasoconstric-
tion and hemostasis, and how these mechanisms may
differ between males (M) and F with age.
It is difficult to reconcile the apparent conflict in bene-
ficial versus deleterious effects of estrogen on neuro-
logical and vascular function unless the effects of age are
considered. Although the mechanisms underlying the
beneficial effects of estrogen on cerebrovascular function
have been studied extensively, studies on the mecha-
nisms responsible for deleterious effects of age and sex
on the modulation of cerebrovascular reactivity are ex-
tremely limited. This lack of understanding emphasizes
the importance of examining the cellular and molecularmechanisms underlying the deleterious effects of age,
sex, and endogenous estrogen on the cerebral vascula-
ture. Thus, in the present studies, the central hypothesis
tested is that age and sex interact in modulating cerebro-
vascular reactivity to vasopressin (VP) by altering the
role of prostanoids in vascular function.Methods
Ethical approval
All animal protocols were in accordance with “U.S.
Government Principles for the Utilization and Care of
Vertebrate Animals Used in Testing, Research and
Training” as detailed in the National Institutes of Health
“Guide for the Care and Use of Laboratory Animals”
and approved by the Texas A & M University Institu-
tional Animal Care and Use Committee.Animals and maintenance
Neurological and vascular effects of estrogen, in both
humans and experimental animals, appear to depend
upon age. Thus, female (F) Sprague–Dawley rats of dif-
fering age groups, which approximate two key stages of
“hormonal age” in humans, were studied. Mature, multi-
gravid, F rats (MA, 5–6 months age) are older than the
virgin F used in most studies, have carried 2–3 previous
pregnancies, and exhibit a longer and somewhat irregu-
lar 5–9-day estrous cycle. Reproductively senescent (RS,
12–14 months age) are the oldest F, have carried 5–6
previous pregnancies, and are acyclic. These two differ-
ent groups of F rats are intended to model two distinctly
different hormonal age groups of women, namely, ma-
ture (perimenopausal) and aged (postmenopausal). This
model has been used successfully to study the effects of
age and estrogen on neurological function and excito-
toxic injury [10-13]. Age-matched male (M) rats were
also studied as a control for the effects of aging. For the
independent effects of age, it was important to identify
the phases of the estrous cycle in female experimental
animals, and thus, daily vaginal smears were used to
determine the stage of the estrous cycle at the time of
experimentation. To eliminate the potential effects of
cyclic surges in estrogen on vascular function, F rats
were only used for experiments while in metestrus/dies-
trus phases, although, previous studies failed to detect
changes in systemic vascular reactivity to VP or phenyl-
ephrine [14]. All rats were purchased from Harlan
(Houston, TX, USA) and housed at the main animal fa-
cility at Texas A & M University. Rats were housed in
pairs, in standard plastic laboratory rat cages, in a well-
ventilated room, maintained at constant temperature
(21°C–26°C), and controlled photoperiod (12 h light:
12 h dark). Sixteen percent protein global diet (soy and
alfalfa-free to minimize dietary phytoestrogens, Harlan
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vided ad libitum.
Plasma estrogen concentration
F rats typically have a short estrous cycle lasting 4–5
days. Plasma estrogen concentrations oscillate markedly
during the phases of the cycle, attaining a peak surge
during proestrus and a nadir during metestrus. Because
the proposed studies focus on the effects of estrogen
levels and age, the endocrine status of all F rats was
determined by vaginal smear. Smears were taken daily,
over 2–3 consecutive cycles (or for approximately
21 days), immediately preceding, and including, the day
of animal sacrifice and blood collection for measurement
of estrogen. Estrous phase was determined by histo-
logical characteristics of the smears [15,16]. Trunk blood
was collected from all animals in ethylenediaminetetra-
acetic acid (EDTA)-coated tubes at the time of sacrifice,
centrifuged, and the plasma was stored at −80°C for later
analysis of plasma 17β-estradiol levels by radioimmuno-
assay (RIA).
Pressurized cannulated MCA vessel preparation
Age-matched M and F rats (mature, MA and reproduc-
tively senescent, RS) were humanely euthanized by rapid
decapitation to avoid artifactual effects of anesthetics
and minimize activation of neural and humoral path-
ways. The middle cerebral arteries (MCA) were isolated
immediately and placed in chilled Krebs-Henseleit bicar-
bonate solution (KHB). The KHB was composed of (in
mM) 118.0 NaCl, 25.0 NaHCO3, 10.0 glucose, 4.74 KCl,
2.5 CaCl2, 1.18 MgSO4, and 1.18 KH2PO4. MCAs from
each animal were cleaned of connective and brain tissue,
and arterial segments were prepared in triplicate. They
were cannulated and tied securely to the pipettes using
11–0 ophthalmic suture. The glass micropipettes were
filled with physiological salt solution (PSS) with albumin,
which contained the following (in mM): 145 NaCl, 4.7
KCl, 2.0 CaCl2, 1.17 MgSO4, 3.0 MOPS, 1.2 NaH2PO4,
5.0 glucose, 2.0 pyruvate, 0.02 EDTA, and 1% bovine
serum albumin (BSA). The cannulated vessel was trans-
ferred to the stage of an inverted microscope (Olympus
CKX41, Olympus, Shinjuku, Japan) equipped with a × 4
objective (numerical aperture of 0.13) and coupled with
a video camera (Hitachi KP-M3AN, Hitachi, Chiyoda-ku,
Japan), video monitor (Pelco PMM12A, Pelco, Clovis, CA,
USA), DVD recorder (Phillips DVDR3475, Phillips,
Amsterdam, The Netherlands), and video micrometer
(Colorado Video 307A, Boulder, CO, USA). Both micropi-
pettes were connected to a single reservoir system and
were gradually adjusted to set the intraluminal pressure of
the vessel at 85 mmHg without allowing flow through the
vessel lumen. Leaks were detected by verifying that intra-
luminal diameter of the pressurized arteriole remainedconstant when the valve to the reservoir system was
closed. Only arterioles that were free of leaks were studied.
The vessel chamber bath (Living Systems TC-09S, Living
Systems, Miami, FL, USA) containing PSS + albumin was
gradually warmed and maintained at 37°C for the duration
of the experiment. Luminal diameter was monitored con-
tinuously throughout the experiment. The vessels were
allowed to equilibrate for 1 h before being pretreated with
pharmacological agents indicated below for 20 min.
Cumulative concentration-response curves to arginine VP
(10−12–10−7 mol/L) were obtained by direct, cumulative
additions of VP into the tissue baths, in the absence or
presence of inhibitors including (1) selective COX-1 in-
hibitor (SC560, 1 μM) or (2) selective cyclooxygenase-2
(COX-2) inhibitor (NS398, 10 μM). Diameter measure-
ments were determined in response to cumulative con-
centrations of VP. Percent constriction was determined by
the following equation: %constriction = (BD −Bx)/BD × 100,
where BD is the steady-state baseline diameter after in-
hibitor incubation and BX is the diameter after each VP
concentration. The concentration of VP that produced
50% of the maximal response (EC50) was calculated in-
dividually from the log concentration-response curve of
each MCA segment.Prostanoid release assay (TXA2 and PGI2)
Vascular prostanoid production by MCA obtained from
age-matched M and F rats (mature, MA and repro-
ductively senescent, RS) was measured using incubation
and radioimmunoassay methods adapted for microves-
sels, as described previously [17]. Briefly, isolated MCA
(3–4 mm axial length) were cleaned of connective tissue
and fat, placed into chilled PSS without BSA (PSS-BSA)
to rest for 60 min. The arterial segments were then
transferred into 0.5 mL microcentrifuge tubes with
450 μL chilled solution and gradually warmed in a water
bath to 37°C for a 45-min pre-incubation. The pre-
incubation medium was carefully aspirated and 300 μL
PSS-BSA alone (basal) or PSS-BSA with VP 10−9 M
(low) or PSS-BSA with VP 10−7 M (high) was added
and incubated at 37°C for 45 min. After incubation, the
incubation media were collected and stored at −80°C
until RIA of stable metabolites of PGI2 (6-keto-pros-
taglandin F1α; 6-keto-PGF1α) and TXA2 (TXB2). MCA
segments were saved and stored at −80°C for dry
weight analysis.Chemical reagents and drugs
The following reagents and drugs were used: 17β-
estradiol (Innovative Research of America, Sarasota, FL,
USA), SC560 and NS398 (Cayman Chemical, Ann
Arbor, MI, USA), arginine VP (Bachem, Torrance, CA,
USA). All other chemicals were of reagent grade quality
Figure 1 VP concentration-response curves in endothelium-
intact pressurized MCA segments. Mature multigravid adult (MA,
4–6 months) female (MA F) or age-matched male rats (MA M) and
reproductively senescent rats (RS, 10–12 months) female (RS F) or
age-matched male rats (RS M). Data points represent means ± SE
(n = 6 rats/group). (a-d) 0.0006≤ P ≤ 0.04, mean values without
common superscript differ significantly at middle and maximal
concentrations of VP.
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Statistics
All data are expressed as means ± SE; n indicates the
number of animals studied. One- or two-way analysis of
variance (ANOVAs) was used to detect significant differ-
ences among means of all experimental groups. If a main
effect was identified, pairwise Student's t tests were
performed to detect significant differences between any
two means of the data groups, with a Bonferroni correc-
tion for multiple comparisons. Vascular function and
prostanoid release data were analyzed using a two-way
ANOVA for sex (M vs. F) and age (MA vs. RS). The ef-
fects of treatment (control (CTL), COX-1 inhibition,
COX-2 inhibition) were analyzed in each experimental
group using a one-way ANOVA. Bonferroni multiple
comparison correction was used. Plasma estradiol levels,
body weight, and uterine weight were analyzed by sex
and age using a two-way ANOVA and Student's t tests.
A P value ≤ 0.05 was considered significant.
Results
Effects of age and sex on estrogen levels, body weight,
and uterine weight
Due to the design of the experiments, the younger MA
F were in metestrus or diestrus phase of the estrous
cycle (as determined by vaginal smears) and thus were
sacrificed during low, non-surge, estradiol levels. Never-
theless, plasma estrogen levels in MA F rats (11.25 ±
1.72 pg/mL) were nearly double those of acyclic RS F
rats (6.59 ± 1.32 pg/mL; P < 0.023). In previous studies,
randomly sampled plasma estradiol levels of young, in-
tact, cycling females averaged 43.9 ± 13 pg/mL [9]. In
contrast, plasma estrogen levels in M rats in the present
study were substantially lower and nearly undetectable
(MA M 2.54 ± 1.06 pg/mL; RS M 0.33 ± 0.09 pg/mL).
Uterine weights did not significantly differ with age
(MA F 0.41 ± 0.04 g/100 g body weight; RS F 0.34 ±
0.03 g/100 g body weight; P > 0.05). Body weight did not
differ with age in F (MA F 303 ± 5.8 g; RS F 303 ± 9.5 g;
P > 0.05); however, RS M were significantly heavier than
MA M (MA M 491 ± 10.9 g; RS M 559 ± 12.3 g; P ≤
0.01). Body weights were significantly different between
M and F in both young MA and older RS rats (P ≤ 0.01).
Effects of age and sex on vascular reactivity to VP
The effects of age and sex on VP-induced vasoconstric-
tion of MCA are shown in Figures 1 and 2 and Table 1.
Comparison of control curves (Figure 1) revealed signifi-
cant age differences in both M and F at the middle VP
concentration. At the maximal VP concentration, age
had a significant effect in F, but not in males, and in
older RS rats, sex also had a significant effect. In olderRS F rats, VP-stimulated constriction was attenuated sig-
nificantly at both middle and maximal VP concentra-
tions as compared with younger MA F. In both MA and
RS M rats, VP-induced constriction did not differ signi-
ficantly from MA F. At the middle VP concentration,
constrictions to VP in RS M were significantly atte-
nuated compared to MA F and MA M; however, sensi-
tivity to VP did not differ.
In MA F, VP produced concentration-dependent con-
strictions with a maximal response of 47.7% and an EC50
of 0.39 nM (Figure 2A). Both COX-1 and COX-2 select-
ive inhibitors, SC560 and NS398, significantly attenuated
constriction at middle and maximal VP concentrations.
Compared with the control group, maximal constriction
was reduced by 58% and 29% by SC560 and NS398,
respectively.
Maximal constrictor response to VP was 32.1% in RS
F with an EC50 of 0.13 nM (Figure 2C). Sensitivity to VP
(EC50) did not differ with age in MA F vs. RS F. SC560
significantly enhanced maximal constriction to VP in RS F
by 39%, yet NS398 had no significant effect. It is import-
ant to note that the reduction in VP constriction in RS F
(as compared to MA F, MA M and RS M) was due to an
enhancement in COX-1 derived dilator prostanoids.
In MA M, VP produced concentration-dependent con-
strictions with a maximal response of 47.6% and an EC50
of 0.10 nM (Figure 2B). At the middle VP concentration,
both SC560 and NS398 attenuated constriction in MA
























































Figure 2 VP concentration-response curves in MCA segments in the absence or presence of selective COX inhibitors. Preparations were
studied in triplicate from each animal group: mature multigravid adult (MA, 4–6 months) female (MA F) (A) or age-matched male rats (MA M) (B),
reproductively senescent (RS, 10–12 months) female (RS F) (C), or age-matched male rats (RS M) (D). Data points represent means ± SE (n = 6
rats/group). (a-f) 0.0001 ≤ P ≤ 0.02, mean values without common superscript differ significantly at middle and maximal concentrations of VP.
In RS M, there were no significant differences among CTL, SC560, and NS398 groups.
Table 1 The effects of age and sex on VP-induced vasoconstriction of endothelium-intact pressurized MCA segments
Group Treatment Maximal response to VP (% Constriction) Relative maximal response to VP Dilator PG Constrictor PG
MA F Control 47.7 ± 3.7 ↑ - -
COX-1 20.0 ± 1.6 0 ↑↑↑
COX-2 33.9 ± 2.4 0 ↑↑
MA M Control 47.6 ± 2.3 ↑ - -
COX-1 41.3 ± 3.1 0 ↑
COX-2 41.7 ± 3.2 0 ↑
RS F Control 32.1 ± 2.7 ↓ - -
COX-1 44.6 ± 3.7 ↑↑ 0
COX-2 27.5 ± .7 0 0
RS M Control 45.5 ± 3.0 ↑ - -
COX-1 41.0 ± 4.6 0 0
COX-2 39.7 ± 2.3 0 0
The effects of age and sex on VP-induced vasoconstriction of endothelium-intact pressurized MCA segments and the relative contributions of constrictor vs. dilator
prostanoids in mature multigravid adult (MA, 4–6 months) female (F) (MA F) or age-matched male (M) rats (MA M) and reproductively senescent (RS, 10–12 months)
female (F) (RS F) or age-matched male (M) rats (RS M). Vasopressin (VP). Prostaglandin (PG). Treatment reflects either control vascular reactivity or reactivity in the
presence of COX-1 (SC560) or COX-2 (NS398) inhibition. Arrows indicate relative differences in response.
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strictions with a maximal response of 45.5% and an EC50
of 0.50 nM (Figure 2D). SC560 and NS398 had no sig-
nificant effect on VP constrictions in older RS M rats at
either middle or maximal VP concentrations.
Effects of age and sex on basal and VP-stimulated
PGI2 release
Basal and VP-stimulated (low concentration 10−9 M;
high concentration 10−7 M) release of 6-keto-PGF1α are
shown in Figure 3. Basal and low concentration VP-
stimulated release of 6-keto-PGF1α did not differ signifi-
cantly between groups (MA F, MA M, RS F, or RS M)
(P > 0.05). Within each of the four groups, VP increased
6-keto-PGF1α production in a concentration-dependent
manner. Low-concentration VP-stimulated 6-keto-PGF1α
release did not differ significantly between groups. How-
ever, low-concentration VP increased 6-keto PGF1α by
fourfold in RS F and fivefold in MA F, MA M, and RS M,
from their respective basal levels. High-concentration VP
increased 6-keto-PGF1α production eightfold in MA F,
sevenfold in MA M, and sixfold in RS F and RS M from
their respective basal levels. At high-concentration VP,
MA F produced significantly more 6-keto PGF1α than RS
F or all other groups.
Effects of age and sex on basal and VP-stimulated TXA2
release
Basal and vasopressin-stimulated (low concentration
10−9 M; or high concentration 10−7 M) release of TXB2Figure 3 Basal and VP-stimulated release of 6-keto-PGF1α by MCA seg
age-matched male rats (MA M) and reproductively senescent (RS, 10–12 m
represent means ± SE (n = 6 rats/group). (a-c) P ≤ 0.0001, mean values withi
significantly different. (*, #) 0.0001≤ P≤ 0.02 mean values between groups
significantly different.are shown in Figure 4. Basal and low concentration VP-
stimulated release of TXB2 did not significantly differ be-
tween groups (MA F, MA M, RS F, or RS M). Within each
of the four groups, VP increased TXB2 production in a
concentration-dependent manner. Low-concentration VP
increased TXB2 production twofold in MA F, RS F, and
MA M and threefold in RS M from their respective basal
levels. High-concentration VP increased TXB2 production
sixfold in MA F, threefold in MA M, and fourfold in RS F
and RS M from their respective basal levels. At high-
concentration VP, MA F produced significantly more
TXB2 than all other groups.
Discussion
The present study is the first to examine the effects of
age and sex on the mechanisms underlying cerebrovas-
cular reactivity to VP in the MCA of Sprague–Dawley
rats. The results reveal the new and novel findings that
both age and sex alter cerebrovascular reactivity by
modulating prostanoid production in the MCA. The
major findings of this study are that (1) VP-induced
constriction is reduced by age in F but is unchanged in
M rats, (2) selective blockade of COX-1 or COX-2 pro-
duced greater age-dependent changes in cerebro-
vascular reactivity to VP in F than in M rats, and (3)
VP-stimulated PGI2 and TXA2 production are reduced
by age in F but not in M rats. In M, there were no
changes in VP-induced vasoconstriction with age.
Additionally, there were no significant differences in
basal, low- or high-VP-stimulated PGI2 or TXA2ments. Mature multigravid adult (MA, 4–6 months) female (MA F) or
onths) female (RS F) or age-matched male rats (RS M). Data points
n groups (MA F, MA M, RS F, RS M) without common superscript are
(MA F vs. MA M vs. RS F vs. RS M) with different superscripts are
Figure 4 Basal and VP-stimulated release of TXB2 by MCA segments. Mature multigravid adult (MA, 4–6 months) female (MA F) or age-
matched male rats (MA M) and reproductively senescent (RS, 10–12 months) female (RS F) or age-matched male rats (RS M). Data points represent
means ± SE (n = 6 rats/group). (a-c) 0.0001≤ P ≤ 0.003, mean values within groups (MA F, MA M, RS F, RS M) without common superscript are
significantly different. (*, #) 0.0001≤ P≤ 0.003 mean values between groups (MA F vs. MA M vs. RS F vs. RS M) with different superscripts are
significantly different.
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keto-PGF1α or TXB2 of young MA M or older RS M
rats. In contrast, there were marked differences in
cerebrovascular reactivity and prostanoid release with
advancing age in F. Older F rats in this study were
acyclic and thus had constant low endogenous estrogen
levels. These older RS F exhibited reduced maximal
constrictor responses to VP, which can be attributed to
enhanced COX-1 derived dilator prostanoid produc-
tion. VP-induced vasoconstriction in younger MA F
(which exhibited estrous cycling) utilized both COX-1
and COX-2 derived constrictor prostanoids. Addition-
ally, high concentration VP-stimulated PGI2 and TXA2
production were enhanced by endogenous estrogen
and decreased with advancing age in F but not in M
rat MCA.
Plasma estrogen levels measured in MA F rats in the
present study were nearly double those of acyclic RS F
rats. In previous studies, randomly cycling female
Sprague–Dawley rats exhibited plasma estrogen levels
significantly higher than cycling MA F rats in the present
study. These higher values are reflective of surge as well as
non-surge plasma estrogen levels [9], whereas the lower
values in MA F rats in the present study are representative
of uniformly non-surge levels in diestrus and metestrus
phases. However, it should be noted that previous studies
have failed to detect any significant changes in vascular
function with the fluctuations in plasma estrogen during
the estrous cycle [14]. Although endogenous estrogenclearly exerts significant effects on vascular function
[9,17], these effects do not appear to vary with the cyclic
changes during the estrous cycle.
Effect of age on mechanisms of cerebrovascular function
Endothelial dysfunction increases in men after age 40
and in women after age 55 [18]. While the exact cause
of the decline in endothelial function is unknown, aging
is usually associated with a reduction in the ability to
elicit endothelium-dependent vasodilation in both ani-
mals and in humans [19,20]. This loss of function oc-
curs via numerous mechanisms leading to attenuated
nitric oxide-mediated dilation [19,20]. In addition to
the age-related changes in nitric oxide, an enhance-
ment of vasoconstrictor prostaglandins further poten-
tiates age-dependent endothelial dysfunction. With
advancing age, both COX-1 and COX-2 expression are
upregulated by oxidative stress, whereas PGI2 receptor
(IP) expression declines [21–24]. There is also indirect
evidence suggesting that untransformed PGH2 (which
interacts with the TXA2 (TP) receptor) is also aug-
mented with aging due to COX-1/COX-2 upregulation
[25,26]. Several studies have reported increases in
TXA2 and TXS mRNA in aorta and mesenteric arteries
with age [23,27]. The results of the present study
confirm and extend these findings regarding effects of
age on vascular function through alterations in the ba-
lance of dilator to constrictor prostanoids, by decrea-
sing production of and/or reactivity to PGI2 and
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PGH2 and TXA2, and that these effects of age also
occur in the cerebrovasculature.
Effects of sex and estrogen on mechanisms of
cerebrovascular function
Women tend to exhibit higher levels of cerebral blood
flow (CBF) than men when they are younger, but this
difference becomes less significant later in life, around
the onset of menopause [28]. Additionally, CBF varies
throughout the menstrual cycle [29] and is altered dur-
ing pregnancy [30]. Thus, chronic exposure to estrogen
positively alters cerebrovascular function, at least in
younger F. Interestingly, there appear to be striking sex-
differences in the modulation of cerebrovascular arterial
tone, with M arteries exhibiting greater myogenic tone
in response to increasing pressure as compared to F [2].
Numerous studies have reported that estrogen enhances
the production and/or the sensitivity of cerebral arteries
to the vasodilatory factors nitric oxide and PGI2
[2,3,5,31,32]. In the cerebrovasculature, estrogen appears
to shift the prostaglandin balance towards greater pro-
duction of vasodilator prostanoids [5], and estrogen
upregulates both COX-1 and PGIS, resulting in en-
hanced PGI2 production [3,5,31], at least in young F rats.
Interestingly, TXA2 production was also slightly, yet sig-
nificantly, elevated in young F animals with estrogen-
treatment, perhaps due to increased COX-1 levels
[31,33]. The age- and sex-dependent shifts in dilator and
constrictor prostanoids observed in the present study re-
veal important new and novel age- and sex-dependent
roles for both constrictor and dilator prostanoids in
cerebrovascular function and clearly establish important
roles for COX-2- and sex-dependent constrictor prosta-
noid production, which are likely due to the effects of
endogenous estrogen to upregulate constrictor prosta-
noid function in F rats [8,9,17].
Divergent effects of age and estrogen on cerebrovascular
function: beneficial vs. deleterious
Earlier findings in human epidemiological [34-36] and
experimental animal studies [37-39] led to the dog-
matic view that estrogen replacement therapy exerts
beneficial effects on neurological and cardiovascular
health and that it is protective against diseases such as
dementia, coronary artery disease, hypertension, and
stroke. An abundance of evidence from experimental
animal studies has established that estrogen does exert
beneficial or protective effects on the cerebrovas-
culature by reducing vascular reactivity and thereby
increasing blood flow through nitric oxide- and vasodi-
lator prostanoid-dependent mechanisms [2-5,31,40,41], at
least in younger animals. In contrast, more recent human
epidemiological findings, such as the HERS [42], HERSII [43], and WHI studies [44], all suggest that, in older
women, estrogen replacement therapy increases the in-
cidences of neurological (dementia and stroke) and vas-
cular (coronary artery disease, hypertension, and
venous thrombosis) diseases. Thus, the role of estrogen
in cardiovascular health and disease has become
controversial. Indeed, recent studies of the systemic
vasculature have clearly established that endogenous es-
trogen exerts deleterious effects on the F vasculature
through upregulation of COX-2, TXS, and TP receptor
expression, thereby enhancing production of, and re-
sponsiveness to, constrictor prostanoids in the F sys-
temic vasculature [8,9,17]. Although numerous studies
have investigated the beneficial effects of estrogen re-
placement in cerebral and systemic vascular beds of
young animals [3,5,17], the present study is the first to
examine the divergent effects of endogenous estrogen
on cerebrovascular reactivity and prostanoid production
in M and F rats at both middle and advanced ages.
These findings suggest that aging and female sex both
exert deleterious effects on cerebrovascular function
through the modulation of constrictor and dilator pros-
tanoid production, which appear to be synergistic in na-
ture, and are likely due to the effects of endogenous
estrogen in the F rat.
Conclusions
The results of this study provide important new and novel
information on the effects of estrogen and advancing age
on cerebrovascular function. Further understanding of the
mechanisms by which estrogen exerts its beneficial vs.
detrimental effects on the cerebrovasculature will perhaps
lead to new age- and sex-specific therapeutic agents de-
signed specifically to target the cerebrovasculature and
other estrogen-responsive tissues.
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